27 juli 2026
15 min
U.S. Science Summit: Biotech veteran Harvey Berger presents an overview of the history of Kendall Square and what is at stake to keep it a leader in life sciences
Dr. Berger, who founded Ariad Pharmaceuticals here in 1991, describes Kendall's transition from candy factories, to Polaroid, to what it is today.
Lyssna på fler avsnitt från
BiotechTV - News
Visar 1–10 av 438 avsnitt
27 juli 2026
U.S. Science Summit: Patient perspectives with sickle cell patient advocate Jimi Olaghere and cystic fibrosis advocate Bob Coughlin
24 min
27 juli 2026
U.S. Science Summit: Curie.Bio Chairman Alexis Borisy and Parabilis Medicines CEO Mathai Mammen discusses the funding environment for biotech and communicating their work to the public
24 min
27 juli 2026
U.S. Science Summit: Flagship Pioneering Founder & CEO Noubar Afeyan discusses his early days in Cambridge and the opportunities it afforded him, science communication, immigrants, and more
24 min
23 juli 2026
U.S. Science Summit: "Who will shape the future of Bio?" with Recursion President & CEO Najat Khan
26 min
23 juli 2026
U.S. Science Summit: Three science communicator social media all-stars share their stories and offer advice on how to tell science stories that resonate with a broad audience
16 min
23 juli 2026
U.S. Science Summit: BiotechTV's Science Correspondent Chloe Kirk introduces the audience to the science communicator social media all-stars who were in attendance at the summit
2 min
23 juli 2026
U.S. Science Summit: Listen to BiotechTV founder Brad Loncar's opening remarks at the inaugural U.S. Science Summit
8 min
22 juli 2026
U.S. Science Summit: Three leading biotech CEOs share the latest on biotech innovation and discuss how the United States can stay on top of an increasingly competitive global landscape
30 min
22 juli 2026
U.S. Science Summit: Dr. Elias Zerhouni discusses the source of what made the United States strong in medical research decades ago and what is at stake to keep supporting it today
19 min
31 maj 2026
ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs
35 min